Forty Seven Inc.


Gilead Sciences is committed to creating a healthier world through innovation and science. With a focus on therapeutic areas such as virology, oncology, and inflammation, Gilead develops and delivers transformative therapies. The company emphasizes health equity, inclusion, and community impact, with a global workforce dedicated to improving lives and advancing public health.

Industries

biotechnology
clinical-trials
health-care
oncology

Nr. of Employees

small (1-50)

Forty Seven Inc.


Patents

Dosing parameters for CD47 targeting therapies to hematologic malignancies

US-12274746-B2

View Details

Dosing parameters for CD47 targeting therapies to hematologic malignancies

US-12194093-B2

View Details

Humanized antibodies against c-Kit

US-12091458-B2

View Details

Humanized, mouse or chimeric anti-CD47 monoclonal antibodies

US-12060423-B2

View Details

Anti-CD47 agent-based treatment of CD20-positive cancer

US-11891450-B2

View Details

Anti-CD47 agent-based ovarian cancer therapy

US-11802153-B2

View Details
View All Patents

Products

Yeztugo (lenacapavir) injection

An approved long-acting injectable formulation of lenacapavir for HIV prevention delivered as an intramuscular injection.

Trodelvy (sacituzumab govitecan) for injection

An antibody–drug conjugate indicated for certain oncology indications and studied in first-line metastatic triple-negative breast cancer.

Yescarta (axicabtagene ciloleucel)

An autologous CAR T-cell therapy for certain hematologic malignancies.

Veklury (remdesivir) for injection

An antiviral small-molecule formulation for intravenous administration developed and deployed during the COVID-19 response.

Harvoni / Sovaldi (sofosbuvir-based regimens)

Oral direct-acting antiviral regimens for treatment of chronic hepatitis C.


Services

Programs to expand patient access to therapies, including medication access initiatives, authorized distributor management and patient-reimbursement assistance.

Competitive grants and investigator funding to support biomedical and translational research in targeted therapeutic areas.

Clinical trial sites and operational support for multicenter studies, including pediatric trials and long-term extension study opportunities.

Centralized medical information services and adverse event/product complaint handling for marketed and investigational products.

Collaborative research agreements, option and license arrangements with industry and academic partners to advance novel programs and technologies.

Expertise Areas

  • Clinical trial management
  • Clinical pipeline and program management
  • Virology drug development
  • Oncology drug development, including cell therapy
  • Show More (8)

Key Technologies

  • Cell therapy (CAR T)
  • Small-molecule therapeutics
  • Targeted protein degraders
  • Long-acting injectable formulation technologies
  • Show More (5)

News & Updates

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.